Compugen (CGEN) Expected to Announce Quarterly Earnings on Monday

Compugen (NASDAQ:CGEN) is anticipated to post its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $1.2850 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 3, 2026 at 8:30 AM ET.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Compugen had a net margin of 47.97% and a return on equity of 47.72%. The business had revenue of $2.18 million for the quarter, compared to the consensus estimate of $1.57 million. On average, analysts expect Compugen to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Compugen Stock Performance

Shares of CGEN opened at $2.35 on Friday. The firm has a market cap of $222.19 million, a P/E ratio of 6.35 and a beta of 2.76. Compugen has a twelve month low of $1.29 and a twelve month high of $3.23. The firm’s 50 day moving average price is $2.27 and its two-hundred day moving average price is $2.26.

Institutional Trading of Compugen

A number of institutional investors have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in shares of Compugen in the fourth quarter worth $104,000. Security National Bank of Sioux City Iowa IA bought a new position in Compugen in the fourth quarter valued at $38,000. Marshall Wace LLP grew its position in Compugen by 135.7% in the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 61,202 shares in the last quarter. State Street Corp increased its stake in Compugen by 3.9% in the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock valued at $603,000 after buying an additional 14,701 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Compugen by 3.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock valued at $2,229,000 after buying an additional 51,565 shares during the last quarter. Institutional investors own 12.22% of the company’s stock.

Wall Street Analyst Weigh In

CGEN has been the topic of a number of research analyst reports. Lake Street Capital initiated coverage on shares of Compugen in a report on Tuesday, April 7th. They set a “buy” rating and a $6.00 price objective on the stock. Leerink Partners reduced their target price on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, May 21st. Wall Street Zen cut Compugen from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $5.00.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.